Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2001-9-19
pubmed:abstractText
In order to determine the comparative efficacy of vancomycin, teicoplanin, levofloxacin, moxifloxacin, and linezolid against methicillin- and ciprofloxacin-resistant Staphylococcus aureus, each agent was tested against 65 genetically different strains using the microbroth dilution method. All of the isolates were typed using the enterobacterial repetitive intergenic consensus polymerase chain reaction to exclude multiple isolates of epidemic clones. Susceptibility testing revealed that all of the isolates were susceptible to vancomycin and teicoplanin. Linezolid exhibited minimum inhibitory concentration (MIC) levels ranging from 1 to 4 mg/l (MIC90, 4 mg/l). The MICs of moxifloxacin and levofloxacin ranged from 0.01 to 8 mg/l (MIC90, 8 mg/l) and 0.25 to 32 mg/l (MIC90. 16 mg/l), respectively. Thus, linezolid is active against methicillin- and ciprofloxacin-resistant Staphylococcus aureus, whereas moxifloxacin may need to be administered at a dose higher than recommended in order to successfully treat serious infections.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Acetamides, http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents, http://linkedlifedata.com/resource/pubmed/chemical/Anti-Infective Agents, http://linkedlifedata.com/resource/pubmed/chemical/Aza Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Ciprofloxacin, http://linkedlifedata.com/resource/pubmed/chemical/Fluoroquinolones, http://linkedlifedata.com/resource/pubmed/chemical/Ofloxacin, http://linkedlifedata.com/resource/pubmed/chemical/Oxazolidinones, http://linkedlifedata.com/resource/pubmed/chemical/Quinolines, http://linkedlifedata.com/resource/pubmed/chemical/Teicoplanin, http://linkedlifedata.com/resource/pubmed/chemical/Vancomycin, http://linkedlifedata.com/resource/pubmed/chemical/linezolid, http://linkedlifedata.com/resource/pubmed/chemical/moxifloxacin
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0934-9723
pubmed:author
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
486-9
pubmed:dateRevised
2005-11-17
pubmed:meshHeading
pubmed-meshheading:11561805-Acetamides, pubmed-meshheading:11561805-Anti-Bacterial Agents, pubmed-meshheading:11561805-Anti-Infective Agents, pubmed-meshheading:11561805-Aza Compounds, pubmed-meshheading:11561805-Base Sequence, pubmed-meshheading:11561805-Ciprofloxacin, pubmed-meshheading:11561805-Drug Resistance, Multiple, pubmed-meshheading:11561805-Fluoroquinolones, pubmed-meshheading:11561805-Humans, pubmed-meshheading:11561805-Methicillin Resistance, pubmed-meshheading:11561805-Microbial Sensitivity Tests, pubmed-meshheading:11561805-Molecular Sequence Data, pubmed-meshheading:11561805-Ofloxacin, pubmed-meshheading:11561805-Oxazolidinones, pubmed-meshheading:11561805-Polymerase Chain Reaction, pubmed-meshheading:11561805-Quinolines, pubmed-meshheading:11561805-Sensitivity and Specificity, pubmed-meshheading:11561805-Staphylococcus aureus, pubmed-meshheading:11561805-Teicoplanin, pubmed-meshheading:11561805-Vancomycin
pubmed:year
2001
pubmed:articleTitle
Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
pubmed:affiliation
Institute of Pathology, Landesnervenklinik Wagner-Jauregg, Linz, Austria. Elisabeth.Presterl@akh-wien.ac.at
pubmed:publicationType
Journal Article